Who are Clover SCB-2019's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): COMIRNATY - BioNTech Manufacturing GmbH, Comirnaty Omicron XBB.1.5, mRNA-1273 vaccine, Spikevax Omicron XBB.1.5, Comirnaty Original/Omicron BA.1, Intramuscularly administered Ad5-nCoV vaccine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/clover-scb-2019.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Clover SCB-2019 — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clover SCB-2019 (Clover SCB-2019) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Recombinant protein vaccine. Area: Immunology / Infectious Disease.

phase 3 Recombinant protein vaccine SARS-CoV-2 spike protein Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

Clover SCB-2019 (Clover SCB-2019) — D'Or Institute for Research and Education. Clover SCB-2019 is a recombinant protein vaccine candidate designed to elicit immune responses against SARS-CoV-2 by presenting stabilized spike protein trimers.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Clover SCB-2019 TARGET	Clover SCB-2019	D'Or Institute for Research and Education	phase 3	Recombinant protein vaccine	SARS-CoV-2 spike protein
COMIRNATY - BioNTech Manufacturing GmbH	COMIRNATY - BioNTech Manufacturing GmbH	Jens D Lundgren, MD	marketed	mRNA vaccine	SARS-CoV-2 spike protein (S protein)
Comirnaty Omicron XBB.1.5	Comirnaty Omicron XBB.1.5	Jules Bordet Institute	marketed	mRNA vaccine	SARS-CoV-2 spike protein (XBB.1.5 variant)
mRNA-1273 vaccine	mRNA-1273 vaccine	University Health Network, Toronto	marketed	mRNA vaccine	SARS-CoV-2 spike protein
Spikevax Omicron XBB.1.5	Spikevax Omicron XBB.1.5	Jules Bordet Institute	marketed	mRNA vaccine	SARS-CoV-2 spike protein (XBB.1.5 variant)
Comirnaty Original/Omicron BA.1	Comirnaty Original/Omicron BA.1	Jules Bordet Institute	marketed	mRNA vaccine	SARS-CoV-2 spike protein (original strain and Omicron BA.1 variant)
Intramuscularly administered Ad5-nCoV vaccine	Intramuscularly administered Ad5-nCoV vaccine	Jiangsu Province Centers for Disease Control and Prevention	marketed	viral vector vaccine	SARS-CoV-2 spike protein

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Recombinant protein vaccine class)

GlaxoSmithKline · 6 drugs in this class
Novavax · 5 drugs in this class
Vaxine Pty Ltd · 2 drugs in this class
D'Or Institute for Research and Education · 2 drugs in this class
Protein Sciences Corporation · 2 drugs in this class
Henogen · 1 drug in this class
Henry M. Jackson Foundation for the Advancement of Military Medicine · 1 drug in this class
Institut National de la Santé Et de la Recherche Médicale, France · 1 drug in this class
National Vaccine and Serum Institute, China · 1 drug in this class
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Clover SCB-2019 — Competitive Intelligence Brief. https://druglandscape.com/ci/clover-scb-2019. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing